SUGT1P4-STRA6LP

Across TCGA pan-cancer cohorts, SUGT1P4-STRA6LP RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of SUGT1P4-STRA6LP’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SUGT1P4-STRA6LP RNA is repressed in tumor relative to normal tissue. In most cancer types SUGT1P4-STRA6LP is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

THCA, BRCA, and KIRP are the cancer types where SUGT1P4-STRA6LP tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SUGT1P4-STRA6LP RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.765	<.001	10	view →
BRCA	All	II,III,IV	−0.429	<.001	6	view →
KIRP	All	All	−0.298	<.001	4	view →
KIRC	All	All	−0.132	.003	4	view →
LUAD	Female	II,III,IV	−0.274	.017	2	view →
LUSC	All	All	−0.197	.009	2	view →
LIHC	All	All	+0.124	.008	2	view →
BLCA	Male	IV	−0.507	.005	1	view →
ESCA	All	All	−0.388	.022	1	view →
KICH	All	All	−0.254	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

SUGT1P4-STRA6LP–THCA

Open the THCA breakdown →